当前位置： SCI文献检索 > CANCER CHEMOTHERAPY AND PHARMACOLOGY期刊下所有文献 > Effect of body weight on the pharmacokinetics of cyclophosphamide in breast cancer patients.

Effect of body weight on the pharmacokinetics of cyclophosphamide in breast cancer patients.

Abstract：

:Cyclophosphamide pharmacokinetics have been studied in 16 female patients with advanced breast cancer. The group included 7 patients who were greater than 20%, less than or equal to 30% over ideal body weight and 5 patients who were greater than 30% over ideal body weight. Cyclophosphamide plasma elimination half-lives ranged between 152 and 984 min (mean 457 min), the apparent volume of distribution between 19.1 and 62.3 1 (mean 36.1 1), and plasma clearance between 25.9 and 166.6 ml/min (mean 69.5 ml/min). There was a significant positive correlation (r = 0.624, P = 0.010) between body weight and plasma elimination half-life, and a significant negative correlation between body weight and cyclophosphamide clearance when normalized to body surface area (r = 0.578, P = 0.019) or normalized to ideal body weight (r = 0.531, P = 0.0345). The apparent volume of distribution did not correlate with body weight. The results show that cyclophosphamide disposition is altered in patients with increased body weight.

journal_name

Cancer Chemother Pharmacol

journal_title

Cancer chemotherapy and pharmacology

authors

Powis G,Reece P,Ahmann DL,Ingle JN

doi

10.1007/BF00570489

subject

Has Abstract

pub_date

1987-01-01 00:00:00

pages

219-22

issue

3

eissn

0344-5704

issn

1432-0843

journal_volume

20

pub_type

临床试验,杂志文章

相关文献

CANCER CHEMOTHERAPY AND PHARMACOLOGY文献大全
  • Clinical outcomes of everolimus in patients with advanced, nonfunctioning pancreatic neuroendocrine tumors: a multicenter study in Korea.

    abstract：PURPOSE:Everolimus is a standard treatment option for advanced pancreatic neuroendocrine tumors (pNETs). This multicenter study evaluated the efficacy and safety of everolimus in low and intermediate grade advanced pNETs. METHODS:Tumors were graded according to the World Health Organization 2010 classification system....

    journal_title：Cancer chemotherapy and pharmacology

    pub_type： 杂志文章,多中心研究

    doi：10.1007/s00280-017-3421-7

    authors： Lee KJ,Cho JH,Lee SH,Song SY,Lee KH,Jeong S,Ryu JK,Woo SM,Bang S,Lee JK,Lee TH,Paik WH,Kim YT,Lee WJ

    更新日期：2017-10-01 00:00:00

  • Phase 1a/1b and pharmacogenetic study of docetaxel, oxaliplatin and capecitabine in patients with advanced cancer of the stomach or the gastroesophageal junction.

    abstract：PURPOSE:The prognosis of gastroesophageal cancer is poor, and current regimens are associated with limited efficacy. The purpose of this study was to explore the safety and preliminary efficacy of docetaxel, oxaliplatin plus capecitabine for advanced cancer of the stomach or the gastroesophageal junction (GEJ). Seconda...

    journal_title：Cancer chemotherapy and pharmacology

    pub_type： 杂志文章,多中心研究

    doi：10.1007/s00280-015-2872-y

    authors： Deenen MJ,Meulendijks D,Boot H,Legdeur MC,Beijnen JH,Schellens JH,Cats A

    更新日期：2015-12-01 00:00:00

  • Synergistic interaction between tetrandrine and chemotherapeutic agents and influence of tetrandrine on chemotherapeutic agent-associated genes in human gastric cancer cell lines.

    abstract：PURPOSE:Tetrandrine (Tet), a bis-benzylisoquinoline alkaloid that was isolated from the dried root of Hang-Fang-Chi (Stephania tetrandra S. Moore), is well known as processing a marked antitumor effect in vitro and in vivo. The aim of this study was to assess the interaction between tetrandrine and chemotherapeutic age...

    journal_title：Cancer chemotherapy and pharmacology

    pub_type： 杂志文章

    doi：10.1007/s00280-007-0416-9

    authors： Wei J,Liu B,Wang L,Qian X,Ding Y,Yu L

    更新日期：2007-10-01 00:00:00

  • Recombinant anti-carcinoembryonic antigen antibodies for targeting cancer.

    abstract：:Antibodies can be used to target cancer therapies to malignant tissue; the approach is attractive because conventional treatments such as chemo- and radiotherapy are dose limited due to toxicity in normal tissues. Effective targeting relies on appropriate pharmacokinetics of antibody-based therapeutics, ideally showin...

    journal_title：Cancer chemotherapy and pharmacology

    pub_type： 杂志文章,评审

    doi：10.1007/pl00014055

    authors： Chester KA,Mayer A,Bhatia J,Robson L,Spencer DI,Cooke SP,Flynn AA,Sharma SK,Boxer G,Pedley RB,Begent RH

    更新日期：2000-01-01 00:00:00

  • Factors affecting sensitivity to antitumor platinum derivatives of human colorectal tumor cell lines.

    abstract：PURPOSE:The aim of this study is to examine the factors affecting sensitivity to cisplatin, carboplatin, and oxaliplatin in human colorectal tumor cell lines. METHODS:Caco-2, DLD-1, HCT-15, HCT116, LS180, SW620, and WiDr cells were used. Their growth inhibition by platinum derivatives was evaluated with a WST-1 assay ...

    journal_title：Cancer chemotherapy and pharmacology

    pub_type： 杂志文章

    doi：10.1007/s00280-007-0640-3

    authors： Kitada N,Takara K,Minegaki T,Itoh C,Tsujimoto M,Sakaeda T,Yokoyama T

    更新日期：2008-09-01 00:00:00

  • Intracellular activation and cytotoxic action of RS-1541 against cultured human tumor cells.

    abstract：:RS-1541, an acyl-derivative of rhizoxin (Fig. 1), is a potent antitumor compound. This agent showed cytotoxicity in vitro on some cultured human tumor cells, although it was less potent than rhizoxin. Rhizoxin exhibited antitumor effects by inhibiting the polymerization of tubulin, whereas RS-1541 did not inhibit tubu...

    journal_title：Cancer chemotherapy and pharmacology

    pub_type： 杂志文章

    doi：10.1007/BF00689446

    authors： Takatori T,Koizumi T,Tokui T,Mitsuhashi Y,Shiraishi A,Tsuruo T

    更新日期：1995-01-01 00:00:00

  • Preclinical pharmacologic evaluation of geldanamycin as an antitumor agent.

    abstract：:The plasma pharmacokinetics of the anti-tumor antibiotic geldanamycin (GM: NSC 122750), a naturally occurring benzoquinoid ansamycin, was characterized in mice and a beagle dog. Concentrations of GM well above 0.1 microgram/ml, which was typically effective against neoplastic cell lines responsive to the drug in vitro...

    journal_title：Cancer chemotherapy and pharmacology

    pub_type： 杂志文章

    doi：10.1007/BF00689048

    authors： Supko JG,Hickman RL,Grever MR,Malspeis L

    更新日期：1995-01-01 00:00:00

  • Phase II study of S-1 as first-line treatment for elderly patients over 75 years of age with advanced gastric cancer: the Tokyo Cooperative Oncology Group study.

    abstract：PURPOSE:This prospective multicenter phase II study was carried out to investigate the efficacy, safety and pharmacokinetics of S-1 monotherapy in elderly patients over 75 years of age, with unresectable advanced or recurrent gastric cancer. METHODS:Patients had measurable or evaluable lesions according to the Japanes...

    journal_title：Cancer chemotherapy and pharmacology

    pub_type： 杂志文章,多中心研究

    doi：10.1007/s00280-009-1114-6

    authors： Koizumi W,Akiya T,Sato A,Sakuyama T,Sasaki E,Tomidokoro T,Hamada T,Fujimori M,Kikuchi Y,Shimada K,Mine T,Yamaguchi K,Sasaki T,Kurihara M

    更新日期：2010-05-01 00:00:00

  • Phase 1 study of new formulation of patritumab (U3-1287) Process 2, a fully human anti-HER3 monoclonal antibody in combination with erlotinib in Japanese patients with advanced non-small cell lung cancer.

    abstract：BACKGROUND:This phase 1 study evaluated the safety, tolerability, pharmacokinetics and efficacy of patritumab (U3-1287) Process 2, a new formulation of fully human anti-HER3 monoclonal antibody in combination with erlotinib, an epidermal growth factor receptortyrosine kinase inhibitor (EGFR-TKI) in prior chemotherapy t...

    journal_title：Cancer chemotherapy and pharmacology

    pub_type： 杂志文章

    doi：10.1007/s00280-016-3231-3

    authors： Shimizu T,Yonesaka K,Hayashi H,Iwasa T,Haratani K,Yamada H,Ohwada S,Kamiyama E,Nakagawa K

    更新日期：2017-03-01 00:00:00

  • The Breast Avastin Trial: phase II study of bevacizumab maintenance therapy after induction chemotherapy with docetaxel and capecitabine for the first-line treatment of patients with locally recurrent or metastatic breast cancer.

    abstract：BACKGROUND:Therapeutic approach for patients with metastatic breast cancer (MBC) is still controversial. This study was conducted to assess the efficacy and safety of bevacizumab in combination with docetaxel plus capecitabine as first-line treatment for MBC. The feasibility of bevacizumab maintenance therapy in this s...

    journal_title：Cancer chemotherapy and pharmacology

    pub_type： 杂志文章,多中心研究

    doi：10.1007/s00280-013-2100-6

    authors： Bisagni G,Musolino A,Panebianco M,De Matteis A,Nuzzo F,Ardizzoni A,Gori S,Gamucci T,Passalacqua R,Gnoni R,Moretti G,Boni C

    更新日期：2013-04-01 00:00:00

  • Efficacy and safety of CT-P6 versus reference trastuzumab in HER2-positive early breast cancer: updated results of a randomised phase 3 trial.

    abstract：PURPOSE:Neoadjuvant CT-P6, a trastuzumab biosimilar, demonstrated equivalent efficacy to reference trastuzumab in a phase 3 trial of HER2-positive early-stage breast cancer (EBC) (NCT02162667). We report post hoc analyses evaluating pathological complete response (pCR) and breast pCR alongside additional efficacy and s...

    journal_title：Cancer chemotherapy and pharmacology

    pub_type： 杂志文章,随机对照试验

    doi：10.1007/s00280-019-03920-4

    authors： Esteva FJ,Baranau YV,Baryash V,Manikhas A,Moiseyenko V,Dzagnidze G,Zhavrid E,Boliukh D,Stroyakovskiy D,Pikiel J,Eniu AE,Li RK,Rusyn AV,Tiangco B,Lee SJ,Lee SY,Yu SY,Stebbing J

    更新日期：2019-10-01 00:00:00

  • Oral bioavailability of docetaxel in combination with OC144-093 (ONT-093).

    abstract：OBJECTIVE:Docetaxel given orally as monotherapy results in low bioavailability of <10%. Previous studies have indicated that the intestinal efflux pump P-glycoprotein (P-gp) prevents uptake from the gut resulting in low systemic exposure to docetaxel. The purpose of this study was to determine the degree of enhancement...

    journal_title：Cancer chemotherapy and pharmacology

    pub_type： 临床试验,杂志文章,随机对照试验

    doi：10.1007/s00280-004-0864-4

    authors： Kuppens IE,Bosch TM,van Maanen MJ,Rosing H,Fitzpatrick A,Beijnen JH,Schellens JH

    更新日期：2005-01-01 00:00:00

  • Preliminary results of M-VAC chemotherapy combined with mild hyperthermia, a new therapeutic strategy for advanced or metastatic transitional cell carcinoma of the urothelium.

    abstract：OBJECTIVE:We evaluated the efficacy and safety of M-VAC chemotherapy combined with mild hyperthermia, a new therapeutic strategy for advanced metastatic transitional cell carcinoma of the urothelium. SUBJECTS AND METHODS:The subjects were 12 patients diagnosed with advanced metastatic transitional cell carcinoma of th...

    journal_title：Cancer chemotherapy and pharmacology

    pub_type： 杂志文章

    doi：10.1007/s00280-009-0964-2

    authors： Yamada Y,Itoh Y,Aoki S,Nakamura K,Taki T,Naruse K,Tobiume M,Zennami K,Katsuda R,Kato Y,Watanabe M,Nishikawa G,Minami M,Nakahira M,Ukai S,Sawada M,Kitamura A,Honda N

    更新日期：2009-11-01 00:00:00

  • ABT-263 sensitizes TRAIL-resistant hepatocarcinoma cells by downregulating the Bcl-2 family of anti-apoptotic protein.

    abstract：PURPOSE:Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) is a promising anticancer agent due to its selective cytotoxicity to transformed cells. However, most human hepatocellular carcinomas (HCC) develop resistance to TRAIL. Thus, there is an urgent need to investigate the molecular targets and the unde...

    journal_title：Cancer chemotherapy and pharmacology

    pub_type： 杂志文章

    doi：10.1007/s00280-011-1763-0

    authors： Wang G,Zhan Y,Wang H,Li W

    更新日期：2012-03-01 00:00:00

  • Phase II trial of S-1 and concurrent radiotherapy in patients with locally advanced pancreatic cancer.

    abstract：PURPOSE:S-1 has a favorable effect in unresectable pancreatic cancer and a potential radiosensitizer. In addition, daily oral administration of S-1 is more convenient than continuous infusion of 5-fluorouracil. This study was designed to evaluate the efficacy and safety of S-1 and concurrent radiotherapy in patients wi...

    journal_title：Cancer chemotherapy and pharmacology

    pub_type： 杂志文章

    doi：10.1007/s00280-008-0836-1

    authors： Kim HM,Bang S,Park JY,Seong J,Song SY,Chung JB,Park SW

    更新日期：2009-02-01 00:00:00

  • Gef gene therapy enhances the therapeutic efficacy of doxorubicin to combat growth of MCF-7 breast cancer cells.

    abstract：PURPOSE:The potential use of combined therapy is under intensive study including the association between classical cytotoxic and genes encoding toxic proteins which enhanced the antitumour activity. The main aim of this work was to evaluate whether the gef gene, a suicide gene which has a demonstrated antiproliferative...

    journal_title：Cancer chemotherapy and pharmacology

    pub_type： 杂志文章

    doi：10.1007/s00280-009-1135-1

    authors： Prados J,Melguizo C,Rama AR,Ortiz R,Segura A,Boulaiz H,Vélez C,Caba O,Ramos JL,Aránega A

    更新日期：2010-05-01 00:00:00

  • Enhancement of cisplatin cytotoxicity by SAHA involves endoplasmic reticulum stress-mediated apoptosis in oral squamous cell carcinoma cells.

    abstract：PURPOSE:The histone deacetylase inhibitor, suberoylanilide hydroxamic acid (SAHA), enhances cisplatin [cis-diammine dichloroplatinum (II)] (CDDP)-induced apoptosis in the oral squamous cell carcinoma (OSCC) cell line by complex, multifunctional mechanisms. We investigated the role of endoplasmic reticulum (ER) stress i...

    journal_title：Cancer chemotherapy and pharmacology

    pub_type： 杂志文章

    doi：10.1007/s00280-009-0969-x

    authors： Suzuki M,Endo M,Shinohara F,Echigo S,Rikiishi H

    更新日期：2009-11-01 00:00:00

  • Comparison of pharmacokinetics and safety profiles of two capecitabine tablet formulations in patients with colon, colorectal or breast cancer.

    abstract：PURPOSE:The objective of this study was to compare the pharmacokinetics and safety of two tablet formulations containing 500 mg of capecitabine (CAS number 154361-50-9) in patients with colon, colorectal or breast cancer. METHODS:The study was a multicentric, open label, randomized, two-treatment, two-period, two-sequ...

    journal_title：Cancer chemotherapy and pharmacology

    pub_type： 杂志文章,多中心研究,随机对照试验

    doi：10.1007/s00280-012-2007-7

    authors： Chachad S,Purandare S,Malhotra G,Naidu R

    更新日期：2013-02-01 00:00:00

  • Timing is everything: intraperitoneal chemotherapy after primary or interval debulking surgery for advanced ovarian cancer.

    abstract：PURPOSE:To evaluate the outcomes of intraperitoneal chemotherapy (IP) compared with those of intravenous chemotherapy (IV) in patients with advanced ovarian cancer after neoadjuvant chemotherapy (NACT) and interval debulking surgery (IDS) or primary debulking surgery (PDS). METHODS:Patients with advanced epithelial ov...

    journal_title：Cancer chemotherapy and pharmacology

    pub_type： 杂志文章

    doi：10.1007/s00280-018-3591-y

    authors： Lee J,Curtin JP,Muggia FM,Pothuri B,Boyd LR,Blank SV

    更新日期：2018-07-01 00:00:00

  • Initial clinical experience with a simultaneous combination of 2,4-diamino-5(3',4'-dichlorophenyl)-6-methylpyrimidine (DDMP) with folinic acid.

    abstract：:DDMP, a diaminopyrimidine folate antagonist, was given to 26 tumor patients in a dosage of 50 mg/m2 per week orally, simultaneously with 3 mg CF i.m. or i.v. The CF dose was increased to 30 mg in patients showing evidence of toxicity, and withdrawn in the absence of toxicity. The dose-limiting toxicity was seen in mye...

    journal_title：Cancer chemotherapy and pharmacology

    pub_type： 临床试验,杂志文章

    doi：10.1007/BF00254043

    authors： Alberto P,Peytremann R,Medenica R,Beretta-Piccoli M

    更新日期：1978-01-01 00:00:00

  • Synergistic cytotoxicity of cisplatin and topotecan or SN-38 in a panel of eight solid-tumor cell lines in vitro.

    abstract：:The cytotoxicity of cisplatin alone and in combination with topotecan (TPT) or SN-38, two novel topoisomerase I (topo I) inhibitors, was determined in a panel of eight well-characterized human solid-tumor cell lines. Interactions between cisplatin and these topo I inhibitors were investigated using three different adm...

    journal_title：Cancer chemotherapy and pharmacology

    pub_type： 杂志文章

    doi：10.1007/s002800050744

    authors： Ma J,Maliepaard M,Nooter K,Boersma AW,Verweij J,Stoter G,Schellens JH

    更新日期：1998-01-01 00:00:00

  • Phase II study of induction gemcitabine and S-1 followed by chemoradiotherapy and systemic chemotherapy using S-1 for locally advanced pancreatic cancer.

    abstract：PURPOSE:S-1 has systemic activity for locally advanced pancreatic cancer (LAPC). Here, the efficacy and safety of induction gemcitabine (GEM) and S-1 (GS) followed by chemoradiotherapy (CRT) and systemic chemotherapy using S-1 for LAPC were assessed. METHODS:The treatment consisted of four cycles of induction GS (S-1 ...

    journal_title：Cancer chemotherapy and pharmacology

    pub_type： 杂志文章

    doi：10.1007/s00280-017-3350-5

    authors： Sudo K,Hara R,Nakamura K,Kita E,Tsujimoto A,Yamaguchi T

    更新日期：2017-07-01 00:00:00

  • Effects of elotuzumab on QT interval and cardiac safety in patients with multiple myeloma.

    abstract：PURPOSE:To assess the effect of elotuzumab on corrected QT (QTc) intervals and cardiac safety. METHODS:Patients with high-risk smoldering multiple myeloma who had been treated with elotuzumab monotherapy (10 or 20 mg/kg) in Study CA204011 (NCT01441973) underwent electrocardiogram (ECG) examination over 8-10 weeks (tre...

    journal_title：Cancer chemotherapy and pharmacology

    pub_type： 杂志文章

    doi：10.1007/s00280-016-3182-8

    authors： Passey C,Darbenzio R,Jou YM,Lynch M,Gupta M

    更新日期：2016-12-01 00:00:00

  • Correction to: Wnt/β-catenin signaling mediates the suppressive effects of diallyl trisulfide on colorectal cancer stem cells.

    abstract：:Unfortunately, the online published article has error in Figure 4. The correct Figure 4 is given here. ...

    journal_title：Cancer chemotherapy and pharmacology

    pub_type： 杂志文章,已发布勘误

    doi：10.1007/s00280-018-3590-z

    authors： Zhang Q,Li XT,Chen Y,Chen JQ,Zhu JY,Meng Y,Wang XQ,Li Y,Geng SS,Xie CF,Wu JS,Zhong CY,Han HY

    更新日期：2018-06-01 00:00:00

  • Preoperative radiotherapy with capecitabine and mitomycin C in locally advanced rectal carcinoma.

    abstract：PURPOSE:To evaluate the efficacy and safety of preoperative radiotherapy with capecitabine and mitomycin C in patients with locally advanced rectal cancer. METHODS:A prospective, open-label, non-randomized, phase II study was performed on 49 patients with locally advanced rectal cancer. Preoperative radiotherapy was c...

    journal_title：Cancer chemotherapy and pharmacology

    pub_type： 杂志文章,随机对照试验

    doi：10.1007/s00280-010-1469-8

    authors： Stojanovic S,Popov I,Radosevic-Jelic L,Micev M,Borojevic N,Nikolic V,Krivokapic Z,Kecmanovic D,Gavrilovic D,Kezic I

    更新日期：2011-09-01 00:00:00

  • Ibrutinib does not prolong the corrected QT interval in healthy subjects: results from a thorough QT study.

    abstract：PURPOSE:Ibrutinib is an orally administered, irreversible Bruton's tyrosine kinase inhibitor for treatment of B-cell malignancy. This study evaluated the effects of single-dose ibrutinib at therapeutic and supratherapeutic exposures on cardiac repolarization in healthy subjects. METHODS:Part 1 used an open-label, two-...

    journal_title：Cancer chemotherapy and pharmacology

    pub_type： 杂志文章

    doi：10.1007/s00280-017-3471-x

    authors： de Jong J,Hellemans P,Jiao JJ,Huang Y,Mesens S,Sukbuntherng J,Ouellet D

    更新日期：2017-12-01 00:00:00

  • Comparative brain and plasma pharmacokinetics and anticancer activities of chlorambucil and melphalan in the rat.

    abstract：:Equimolar doses of chlorambucil and melphalan (both 10 mg/kg) were administered i.v. to anesthetized rats, and the plasma and brain concentrations of chlorambucil, its metabolites 3,4-dehydrochlorambucil and phenylacetic mustard, and melphalan were determined by high-performance liquid chromatography from 5 to 240 min...

    journal_title：Cancer chemotherapy and pharmacology

    pub_type： 杂志文章

    doi：10.1007/BF00262729

    authors： Greig NH,Sweeney DJ,Rapoport SI

    更新日期：1988-01-01 00:00:00

  • A phase I/II study of vinorelbine, doxorubicin, and methotrexate with leucovorin rescue as first-line treatment for metastatic breast cancer.

    abstract：PURPOSE:This study was performed to determine the maximum tolerated dose (MTD) and toxicity of vinorelbine when used in combination with doxorubicin and methotrexate with leucovorin rescue in women with metastatic breast cancer. METHODS:Enrolled in the study were 23 women with metastatic breast cancer who had not rece...

    journal_title：Cancer chemotherapy and pharmacology

    pub_type： 临床试验,杂志文章

    doi：10.1007/s002800050929

    authors： Subramanyan S,Abeloff MD,Bond SE,Davidson NE,Fetting JH,Gordon GB,Kennedy MJ

    更新日期：1999-01-01 00:00:00

  • In vitro evaluation of the growth inhibition and apoptosis effect of mifepristone (RU486) in human Ishikawa and HEC1A endometrial cancer cell lines.

    abstract：PURPOSE:To determine the growth inhibitory effects of mifepristone on endometrial cancer cell growth and evaluate its effect on apoptosis using HEC-1-A and Ishikawa human endometrial cancer cell lines. METHODS:The human endometrial cancer cell lines, HEC-1-A and Ishikawa, were cultured in vitro. MTT assays were comple...

    journal_title：Cancer chemotherapy and pharmacology

    pub_type： 杂志文章

    doi：10.1007/s00280-007-0628-z

    authors： Navo MA,Smith JA,Gaikwad A,Burke T,Brown J,Ramondetta LM

    更新日期：2008-08-01 00:00:00

  • A phase I, pharmacokinetic, and pharmacodynamic evaluation of the DNA methyltransferase inhibitor 5-fluoro-2'-deoxycytidine, administered with tetrahydrouridine.

    abstract：PURPOSE:Inhibitors of DNA (cytosine-5)-methyltransferases (DNMT) are active antineoplastic agents. We conducted the first-in-human phase I trial of 5-fluoro-2'-deoxycytidine (FdCyd), a DNMT inhibitor stable in aqueous solution, in patients with advanced solid tumors. Objectives were to establish the safety, maximum tol...

    journal_title：Cancer chemotherapy and pharmacology

    pub_type： 杂志文章,多中心研究

    doi：10.1007/s00280-014-2674-7

    authors： Newman EM,Morgan RJ,Kummar S,Beumer JH,Blanchard MS,Ruel C,El-Khoueiry AB,Carroll MI,Hou JM,Li C,Lenz HJ,Eiseman JL,Doroshow JH

    更新日期：2015-03-01 00:00:00